CombiMatrix Names Dr. Shane Grey to Its Scientific Advisory Board.Business Editors/Science Writers/Health/Medical Writers BIOWIRE2K NEWPORT BEACH, Calif.--(BUSINESS WIRE)--July 30, 2003 Acacia Research Corporation (Nasdaq:CBMX)(Nasdaq:ACTG ACTG Acting ACTG AIDS Clinical Trial Group ACTG Actuating/Actuator ) announced today that CombiMatrix has named Shane Grey, Ph.D. to its Scientific Advisory Board. Dr. Grey is currently an Assistant Professor in Surgery, Department of Surgery, Harvard Medical School Harvard Medical School (HMS) is one of the graduate schools of Harvard University. It is a prestigious American medical school located in the Longwood Medical Area of the Mission Hill neighborhood of Boston, Massachusetts. . "As CombiMatrix becomes a more diversified life science company, we welcome opportunities to work with experts such as Dr. Grey who has research experience in many areas, including the viral delivery of therapeutic genes and nucleic acids Nucleic acids The cellular molecules DNA and RNA that act as coded instructions for the production of proteins and are copied for transmission of inherited traits. . This expertise will aid the development of Express Track(SM) our siRNA drug discovery initiative," commented Amit Kumar, Ph.D., President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of CombiMatrix. "With the advice of Dr. Grey as well as our current Scientific Advisory Board Members, we expect to build a strong drug discovery and development foundation at CombiMatrix." "I am looking forward to working with CombiMatrix in the area of siRNA drug development as well as other therapeutic programs in consideration. I expect my clinical experience will augment the expertise already assembled by CombiMatrix," said Dr. Grey. "I am impressed by CombiMatrix's array technology as well as its strategy and vision, and I hope to be an active contributor in helping to build the company." Dr. Grey's research is focused on utilizing novel, state of the art gene based therapies to treat important inflammatory diseases such as auto-immune conditions like diabetes mellitus diabetes mellitus Disorder of insufficient production of or reduced sensitivity to insulin. Insulin, synthesized in the islets of Langerhans (see Langerhans, islets of), is necessary to metabolize glucose. In diabetes, blood sugar levels increase (hyperglycemia). . Dr. Grey has won numerous academic awards, sits on a number of prestigious review boards and editorial committees. Some of these include the Juvenile Diabetes juvenile diabetes n. Insulin-dependent diabetes. Foundation International, the National Health and Medical Research Council The National Health and Medical Research Council (NHMRC) is Australia's peak funding body for medical research, with a budget of nearly A$500M a year . The Council was established to develop and maintain health standards and is responsible for implementing the of Australia, the Journal of Immunology The Journal of Immunology (The JI) is an academic journal that publishes basic and clinical studies in all aspects of immunology. It is owned and published by The American Association of Immunologists. Having an impact factor of 6. and Immunology Today and others. Dr. Grey received his Ph.D. in 1995 in Immunology and Pathology from Monash University in Australia. Dr. Grey then moved to the Sandoz Center for Immunobiology in Boston for post-doctoral research in human immunology, gene therapy and transplantation. This year Dr. Grey will move his research to the Garvan Institute of Medical Research The Garvan Institute of Medical Research was founded in 1963 by the Sisters of Charity. Initially a research department of St Vincent's Hospital in Sydney, it is now one of Australia's largest medical research institutions with approximately 400 scientists, students and support , in Sydney, Australia (www.garvan.org.au). This institute is an international leader in gene based medical research. About Acacia Research Corporation Acacia Research Corporation comprises two operating groups, Acacia Technologies Group and CombiMatrix Group. The CombiMatrix group is developing a platform technology to rapidly produce customizable active biochips, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. CombiMatrix's technology has a wide range of applications including DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. synthesis/diagnostics, drug discovery, and immunochemical im·mu·no·chem·is·try n. The chemistry of immunologic phenomena, as of antigen-antibody reactions. im detection. CombiMatrix's Express Track(SM) drug discovery program is a systems biology approach, using its technology, to target common viral diseases with siRNA compounds. The initial focus of Express Track(SM) are the following viral diseases: Virus Collaborator SARS NIAID/USAMRIID HIV type 1 irsiCaixa-Dr. Bonaventura Clotet HIV type 2 To Be Announced West Nile virus To Be Announced Human Papillomavirus type 16 To Be Announced Human Herpes 8 (Kaposi's sarcoma) To Be Announced Smallpox (Variola) To Be Announced Influenza virus A To Be Announced Influenza virus B To Be Announced Hepatitis C To Be Announced The Acacia Technologies group licenses its DMT See DSL. and V-Chip technologies to media and electronics companies. The DMT technology covers the transmission and receipt of digital audio and digital video content, commonly known as audio on-demand, video on-demand, and audio/video streaming, and is supported by 5 U.S. and 17 international patents. Acacia Research-Acacia Technologies (Nasdaq:ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups. Information about Acacia Research Corporation and the Acacia Technologies group is available at www.acaciaresearch.com. Information about the CombiMatrix group is available at www.combimatrix.com. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion